Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

NCT06797401 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemias

Interventions

DRUG: RBD5044
DRUG: Placebo

Sponsor

Ribocure Pharmaceuticals AB